LCTX
Lineage Cell Therapeutics Inc
0.971$
-5.7%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 43.3% | 49.9% | 18.0% | 24.6% | 35.8% | 45.8% | 40.8% | 63.9% | 48.5% | 38.1% | 45.0% | 52.5% | |
| 39.4% | 44.6% | 15.5% | 21.3% | 23.2% | 7.6% | 30.2% | 31.9% | 9.2% | 35.1% | 40.4% | 36.2% | |
| 39.4% | 45.4% | 15.9% | 22.0% | 30.2% | 24.5% | 38.5% | 33.4% | 46.8% | 35.1% | 42.2% | 49.5% | |
| 1.4% | 1.7% | 0.8% | 1.8% | 3.7% | 19.7% | 0.0% | 29.3% | 0.2% | 0.7% | 0.6% | 1.4% | |
| 0.4% | 0.0% | – | 0.0% | 0.0% | 0.0% | – | – | 0.0% | – | – | – | |
| 3.8% | 8.0% | 3.9% | 3.2% | 5.7% | 6.5% | 5.2% | 2.8% | 4.6% | – | – | – | |
| – | – | – | – | – | 8.5% | 9.9% | 6.1% | 8.6% | 10.6% | 9.4% | 9.5% | |
| 51.9% | 35.5% | 7.2% | 4.0% | 3.1% | 38.5% | 43.6% | 26.8% | 37.8% | 46.1% | 41.1% | 28.2% | |
| 16.3% | 19.2% | 8.5% | 5.2% | 9.3% | 11.3% | 11.9% | 47.9% | 41.8% | 38.6% | 32.0% | 61.5% | |
| 9.5% | 13.2% | 6.2% | 4.0% | 6.7% | 5.2% | 7.2% | 27.0% | 15.3% | 17.8% | 12.3% | 10.1% | |
| 0.2% | 0.1% | 0.8% | 0.2% | 0.3% | 1.0% | 1.2% | 0.5% | 0.8% | 0.9% | 1.0% | 0.8% | |
| 3.1% | 3.0% | 1.1% | 0.5% | 2.3% | 1.9% | 2.4% | 2.0% | 1.9% | 2.0% | 1.0% | 2.1% | |
| 0.5% | 5.3% | 0.8% | 0.0% | – | – | – | – | – | – | – | – | |
| 48.7% | 28.4% | 82.7% | 93.9% | 92.3% | 90.0% | 89.1% | 52.8% | 59.3% | 62.8% | 69.2% | 39.6% | |
| -243.2% | -242.1% | -137.7% | -124.9% | -257.6% | -217.9% | -272.4% | -193.1% | -293.8% | -381.0% | -356.4% | -414.8% | |
| 88.7% | 84.2% | 69.8% | 66.1% | 124.8% | 116.0% | 139.0% | 94.2% | 137.3% | 170.9% | 176.8% | 204.4% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.